Results 91 to 100 of about 105,114 (279)

Cell‐Selective Delivery of RIBOTACs via an Anti‐EGFR Nanobody for Pancreatic Cancer Treatment

Advanced Science, EarlyView.
This study introduces an innovative strategy for the tumor‐selective catalytic degradation of oncogenic non‐coding RNA by interfacing a ribonuclease‐recruiting small molecule (RIBOTAC) with an EGFR‐targeting nanobody via a CTSB (Cathepsin B)‐responsive linker.
Tianli Luo, Yijuan Wang, Dengwang Chen, Yinghan Zhang, Yi Shuai, Hualiang Yao, Tao Jiang, Hang Jiang, Ming Zhong, Xiangeng Wang, Ziwei Wang, Chenchen Xu, Ajay Goel, Hoi Tang MA, Feng Gao, Xin Wang   +15 more
wiley   +1 more source

THE DIFFERENCES OF APOPTOSIS EFFECTS BETWEEN COMBINATION OF MELOXICAM WITH GEMCITABINE-CARBOPLATIN CHEMOTHERAPY COMPARED TO GEMCITABINE-CARBOPLATIN CHEMOTHERAPY ALONE IN UROTHELIAL CARCINOMA CULTURE CELLS

Jurnal Urologi Indonesia, 2019
Objective: To determine the differences of apoptosis effect between the combination of meloxicam and gemcitabine-carboplatin compared to gemcitabine-carboplatin alone as the standard of chemotherapy care in urothelial carcinoma culture cells.
Ananta Cahyo Nugroho, Lukman Hakim, Wahjoe Dajtisoesanto, Doddy M Soebadi   +3 more
doaj   +1 more source

Pasta, a Versatile Transcriptomic Clock, Maps the Chemical and Genetic Determinants of Aging and Rejuvenation

Advanced Science, EarlyView.
Pasta is a transcriptomic aging clock built on an age‐shift learning framework and trained on 17 000 samples across 21 datasets. It accurately predicts relative biological age across tissues, platforms, and species, captures stemness‐to‐senescence transitions, and identifies age‐modulatory perturbations.
Jérôme Salignon, Maria Tsiokou, Patricia Marqués, Enriqueta Rodríguez‐Diaz, Hazel Ang, Federico Pietrocola, Christian G. Riedel   +6 more
wiley   +1 more source

Antineoplastic mechanism of gemcitabine on tumor cells with different TP53/p53 subtypes

, 2014
The aim of this chapter is to provide updated information on the mechanisms by which gemcitabine acts on tumor cells with different TP53 gene backgrounds.
Salvadori, Daisy Maria Favero, da Silva, Glenda Nicioli   +1 more
core   +1 more source

Gemcitabine-Induced Pulmonary Toxicity: A Case Report of Pulmonary Veno-Occlusive Disease

, 2015
Introduction Gemcitabine is a chemotherapeutic agent frequently used by for the treatment of several malignancies both in the adjuvant and metastatic setting.
Célia Turco, Marine Jary, Christophe Borg, Thierry Nguyen, Philippe Manzoni, Bruno Degano, Marie-Blanche Valnet Rabier, Mélanie Moltenis, Bruno Genet, Bruno Heyd, Stefano Kim   +10 more
core   +1 more source

Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor [PDF]

, 2012
Gemcitabine is indicated in combination with cisplatin as first-line therapy for solid tumours including non-small cell lung cancer (NSCLC), bladder cancer and mesothelioma.
FARDOD O’KELLY, Nikolaidis, Georgios, ARMELLE MEUNIER, DONAL HOLLYWOOD, Dockry, Éilis, O'Byrne, Kenneth J., TOMAS J. EKSTRÖM, KENNETH J. O’BYRNE, MALIN ALMGREN, GEORGIOS NIKOLAIDIS, ANTOINETTE S. PERRY, Perry, Antoinette S., ANNE-MARIE BAIRD, STEVEN G. GRAY, Gray, Steven G., Baird, Anne-Marie, Almgren, Malin, Ekström, Tomas J., Hollywood, Donal, EILIS DOCKRY, O'Kelly, Fardod, Meunier, Armelle   +21 more
core   +1 more source

RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine

International Journal of Nanomedicine, 2019
Wenchao Liu1,2, Yujia Mao1,2, Xiaoyi Zhang1,2, Yaonan Wang1,2, Jianhui Wu1,2, Shurui Zhao1,2, Shiqi Peng1,2, Ming Zhao1–3 1Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of ...
Liu W, Mao Y, Zhang X, Wang Y, Wu J, Zhao S, Peng S, Zhao M   +7 more
doaj  

Tislelizumab combined with gemcitabine plus cisplatin for muscle-invasive upper tract urothelial carcinoma: A retrospective single-center cohort analysis

Journal of International Medical Research
Objective Gemcitabine plus cisplatin is the standard adjuvant regimen for postoperative management of muscle-invasive upper tract urothelial carcinoma. This study investigated whether adding tislelizumab to gemcitabine plus cisplatin improves outcomes in
Jingwen Zhang, Yongshuang Xiao, Donghua Cai, Hua Zhu, Wei Zhong   +4 more
doaj   +1 more source

Targeting Tex10 Overcomes Oxaliplatin Resistance by Competitively Disrupting the Non‐Canonical BAF Complex in Colorectal Cancer

Advanced Science, EarlyView.
This study reveals that Tex10 drives oxaliplatin resistance in colorectal cancer by competitively binding BRD9 to disrupt the ncBAF complex, thereby suppressing AMBRA1 transcription and ULK1‐mediated autophagy. Gemcitabine is identified as a direct Tex10 inhibitor that restores autophagy and overcomes resistance.
Ping Xu, Jie Huang, Xiaojin Gao, Lin Deng, Yanheng Deng, Denglu Wang, Chunlei Yu, Yunxiang Zhang, Jingdong Li, Xiaocong Xiang   +9 more
wiley   +1 more source

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR‐T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy

Advanced Science, EarlyView.
This study shows that a PARP inhibitor combined with anlotinib, administered as bridging therapy, preconditions the tumor microenvironment to enhance the infiltration and antitumor activity of subsequently infused CAR‐T cells across preclinical ovarian cancer models, supporting bridging therapy as a promising strategy to address limited CAR‐T cell ...
Huayi Li, Minghua Xiang, Qiuyang Xu, Jiahao Liu, Xiaofei Jiao, Wei Mu, Xiaoying Lv, Kangjia Tao, Yu Xu, Dongchen Zhou, Wenjian Gong, Danmei Yan, Yixin Hu, Sen Xu, Bingbing Zhao, Jundong Li, Yongkang Gai, Guang Hu, Li Zhu, Qinglei Gao, Yong Fang   +20 more
wiley   +1 more source